Genetic strategies to individualize supportive care

Journal of Clinical Oncology

Volumn 20, Issue 12, 2002, Pages 2765-2767

  McLeod, Howard L ^a  

^a Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BETA TUBULIN; CARBOPLATIN; CODEINE; COLONY STIMULATING FACTOR; CYTOCHROME P450 2D6; DIHYDROPYRIMIDINE DEHYDROGENASE; DINUCLEOTIDE; DNA; ERYTHROPOIETIN; FLUOROURACIL; GLUCOCORTICOID; GLUCURONOSYLTRANSFERASE; IMATINIB; IRINOTECAN; MERCAPTOPURINE; MORPHINE; ONDANSETRON; PACLITAXEL; PLATINUM DERIVATIVE; RNA; SEROTONIN 3 ANTAGONIST; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TRASTUZUMAB; TROPISETRON;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; DIARRHEA; EDITORIAL; GENE EXPRESSION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 0037096956     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.20.12.2765     Document Type: Editorial

References (29)

1. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
2. Imatinib mesylate: A new oral targeted therapy
3. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
4. Pharmacogenomics: Unlocking the human genome for better drug therapy
5. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia
6. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine
7. Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
8. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT 1A 1 promoter polymorphism
9. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
10. UGT1A1* 28 polymorphism as a determinant of irinotecan disposition and toxicity
11. Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations
12. Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer
13. Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer
14. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy
15. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil
16. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer
17. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes
18. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: A comparison of their pharmacology and clinical efficacy
19. Unravelling the functional genomics of the human CYP 2D6 gene locus
20. The pharmacogenetics of codeine hypoalgesia
21. The hypoalgesic effect of tramadol in relation to CYP 2D6
22. Pharmacogenetics: A new diagnostic tool in the management of antidepressive drug therapy
23. Identification of polymorphisms in the UGT2B7 promoter: Association with morphine glucuronidation in patients
24. DNA microarray technology and antimicrobial drug discovery
25. Etiology of differences in hematocrit between males and females: Sequence-based polymorphisms in erythropoietin and its receptor
26. Novel single nucleotide polymorphisms of the human colony-stimulating factor 2 (CSF2) gene identified by sequencing the entire gene
27. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease
28. The procarcinogen hypothesis for bladder cancer: Activities of individual drug metabolizing enzymes as risk factors
29. Ethical and legal implications of pharmacogenomics